Tumor endothelial cell abnormalities
肿瘤内皮细胞异常
基本信息
- 批准号:8325609
- 负责人:
- 金额:$ 24.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-01 至 2014-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdenocarcinomaAdultAngiogenesis InhibitorsBloodBlood CirculationBlood VesselsBone MarrowBone Marrow AblationBreast CarcinomaCell LineCellsClinicClinical ResearchClinical TrialsClone CellsDissectionDrug resistanceDrug usageEmployee StrikesEndothelial CellsEndotheliumEngraftmentGenesGoalsHeterogeneityHomingHumanKnowledgeLaboratoriesLasersMammary NeoplasmsMesenchymal Stem CellsMolecularMolecular ProfilingMouse Mammary Tumor VirusMusMyeloid CellsNeoplasm MetastasisNeoplasmsNeoplasms in Vascular TissueNutrientOxygenPECAM1 geneProstate carcinomaProstatic NeoplasmsStem cellsTestingTransgenic MiceTumor Biologyantiangiogenesis therapybasebonecalcificationcancer therapycell typedesignfeedingmineralizationmouse modelneoplastic cellnovelprogenitorprogramstumortumor progression
项目摘要
The idea that tumors could be eradicated by destroying tumor-associated blood vessels was first proposed
over 30 years ago. Today there are about 11 anti-angiogenic drugs in clinical trials. But the results of most
clinical studies to date have so far been disappointing. The idea behind anti-angiogenesis (anti-endothelial)
therapy is that the endothelial cells lining tumor blood vessels are homogeneous, normal, are not mutable,
and wlll not develop drug resistance in contrast to tumor cells. However, that basic assumption has been
challenged by recent studies showing morphological and molecular changes (e.g. ectopic calcification) and
striking heterogeneity in tumor-specific endothelial cells. Endothelial cells conscripted by a growing tumor
may evade anti-angiogenic strategies through diverse, acquired mechanisms. For example, tumor-specific
endothelial cells may be derived from multiple cell types. Including sprouting endothelium, bone marrowderived
vascular progenitors, trans-differentiated myeloid cells, and multi-potent mesodermal stem cells. It is
surprising, then, that most anti-angiogenic therapies today are routinely tested on normal endothelial cell
lines in the laboratory. To address this problem, our goals are: 1) To use transgenic mouse models of breast
and prostate carcinoma to isolate and characterize tumor-specific endothelial cells from breast and prostate
tumors. 2) To determine the relationship between tumor blood vessel calcification and tumor progression
and metastasis. 3) To determine the tumor-specific "homing" and vascular differentiation potential of adult
mesenchymal stem cells in tumor-bearing mice. 4) And to use laser capture micro-dissection and microarrays
to identify a molecular signature in tumor-specific endothelial cells as tumors progress from the
earliest neoplasia to adenocarcinoma. It Is not known why anti-angiogenic therapies, which hold great
promise in the treatment of cancer, have not succeeded in the clinic. Our study seeks to better understand
the biology of tumor-specific endothelial cells through rigorous characterization of freshly Isolated cells and
high-throughput gene analysis to identify novel genes and gene networks. The long-term goal Is to use this
new knowledge for the rational design of more effective anti-angiogenic strategies.
首先提出了通过破坏肿瘤相关血管来根除肿瘤的想法
30多年前目前,大约有11种抗血管生成药物正在进行临床试验。但大多数人的结果
迄今为止的临床研究结果令人失望。抗血管生成(anti-endothelial)
治疗的方法是肿瘤血管的内皮细胞是同质的、正常的、不可变异的,
并且与肿瘤细胞相比不会产生耐药性。然而,这一基本假设
最近的研究显示形态和分子变化(例如异位钙化),
肿瘤特异性内皮细胞中的显著异质性。内皮细胞被生长的肿瘤征召
可能通过多种获得性机制逃避抗血管生成策略。例如,肿瘤特异性
内皮细胞可以来源于多种细胞类型。包括新生内皮细胞,骨髓源性
血管祖细胞、转分化的骨髓细胞和多能中胚层干细胞。是
令人惊讶的是,目前大多数抗血管生成疗法都是在正常内皮细胞上进行常规试验,
实验室里的线针对这一问题,我们的目标是:1)利用转基因小鼠乳腺癌模型,
和前列腺癌中分离和鉴定肿瘤特异性内皮细胞
肿瘤的2)确定肿瘤血管钙化与肿瘤进展的关系
和转移。3)为了确定肿瘤特异性“归巢”和血管分化潜能,
间充质干细胞在荷瘤小鼠。4)使用激光捕获显微切割和微阵列
当肿瘤从血管内皮细胞进展时,
最早的肿瘤到腺癌。目前尚不清楚为什么抗血管生成疗法,其中持有伟大的
在治疗癌症方面很有希望,但在临床上还没有成功。我们的研究旨在更好地了解
通过对新鲜分离的细胞进行严格表征,
高通量基因分析以鉴定新基因和基因网络。长期目标是利用这个
为合理设计更有效的抗血管生成策略提供了新的知识。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew Carl Dudley其他文献
Andrew Carl Dudley的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew Carl Dudley', 18)}}的其他基金
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices
肿瘤内皮细胞对促转移纤维蛋白基质的调节
- 批准号:
10356164 - 财政年份:2021
- 资助金额:
$ 24.9万 - 项目类别:
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices
肿瘤内皮细胞对促转移纤维蛋白基质的调节
- 批准号:
10179715 - 财政年份:2021
- 资助金额:
$ 24.9万 - 项目类别:
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices
肿瘤内皮细胞对促转移纤维蛋白基质的调节
- 批准号:
10573196 - 财政年份:2021
- 资助金额:
$ 24.9万 - 项目类别:
Mechanisms of tumor escape from anti-angiogenic therapy
肿瘤逃避抗血管生成治疗的机制
- 批准号:
8693221 - 财政年份:2014
- 资助金额:
$ 24.9万 - 项目类别:
Mechanisms of tumor escape from anti-angiogenic therapy
肿瘤逃避抗血管生成治疗的机制
- 批准号:
8887312 - 财政年份:2014
- 资助金额:
$ 24.9万 - 项目类别:
Targeting the vasculature to enhance anti-tumor immunity
靶向血管系统增强抗肿瘤免疫力
- 批准号:
10399410 - 财政年份:2014
- 资助金额:
$ 24.9万 - 项目类别:
Targeting the vasculature to enhance anti-tumor immunity
靶向血管系统增强抗肿瘤免疫力
- 批准号:
10092966 - 财政年份:2014
- 资助金额:
$ 24.9万 - 项目类别:
Targeting the vasculature to enhance anti-tumor immunity
靶向血管系统增强抗肿瘤免疫力
- 批准号:
10621205 - 财政年份:2014
- 资助金额:
$ 24.9万 - 项目类别:
Characterizing tumor endothelial cell abnormalities to develop rational anti-angi
表征肿瘤内皮细胞异常以开发合理的抗血管治疗
- 批准号:
7708266 - 财政年份:2009
- 资助金额:
$ 24.9万 - 项目类别:
Characterizing tumor endothelial cell abnormalities to develop rational anti-angi
表征肿瘤内皮细胞异常以开发合理的抗血管治疗
- 批准号:
8231654 - 财政年份:2009
- 资助金额:
$ 24.9万 - 项目类别:
相似国自然基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
- 批准号:30840003
- 批准年份:2008
- 资助金额:12.0 万元
- 项目类别:专项基金项目
相似海外基金
Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
- 批准号:
478914 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
- 批准号:
23K14913 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
- 批准号:
23K15035 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
- 批准号:
10442874 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
- 批准号:
10657069 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
- 批准号:
23K08326 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
- 批准号:
23K14614 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
- 批准号:
23K15075 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
- 批准号:
23H02698 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
- 批准号:
10743611 - 财政年份:2023
- 资助金额:
$ 24.9万 - 项目类别: